Bone-Targeted Agents. Preventing Skeletal Complications in Prostate Cancer

Urologic Clinics of North America

Volumn 39, Issue 4, 2012, Pages 533-546

  Morgans, Alicia K ^a   Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

ADT; Bone; Prostate cancer; Side effects of therapy; Skeletal complications; Skeletal related events

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DENOSUMAB; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; MITOXANTRONE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SAMARIUM 153; STEROID; STRONTIUM 89; TESTOSTERONE; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; ANEMIA; BONE DENSITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER SURVIVOR; CASTRATION RESISTANT PROSTATE CANCER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG SAFETY; EXTERNAL BEAM RADIOTHERAPY; FALLING; FRAGILITY FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOGONADISM; JAW OSTEONECROSIS; KIDNEY DISEASE; METASTASIS FREE SURVIVAL; NAUSEA; ORCHIECTOMY; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SPINAL CORD COMPRESSION; SPINE FRACTURE; VENOUS THROMBOEMBOLISM;

ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; CLODRONIC ACID; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; MALE; OSTEOCLASTS; OSTEOPOROSIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SAMARIUM; TOREMIFENE;

EID: 84867676607     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2012.07.009     Document Type: Review

References (72)

1. Eriksen E.F., Colvard D.S., Berg N.J., et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988, 241(4861):84-86.
2. Boyce B.F., Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007, 9(Suppl 1):S1.
3. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292(4):490-495.
4. Berruti A., Dogliotti L., Bitossi R., et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000, 164:1248-1253.
5. Clarke N.W., McClure J., George N.J. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol 1993, 24:286-290.
6. Clarke N.W., McClure J., George N.J. Monomorphic evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991, 68:74-80.
7. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998, 19(1):18-54.
8. Micahelson M.D., Marujo R.M., Smith M.R. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res 2004, 10(8):2705-2708.
9. Logothetis C.J., Lin S.H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005, 5(1):21-28.
10. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
11. Kahn D., Weiner G.J., Ben-Haim S., et al. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood 1994, 83:958-963.
12. Hauschka P.V., Mavrakos A.E., Iafrati M.D., et al. Growth factors in bone matrix: isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 1986, 261:12665-12674.
13. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
14. Saad F., Gleason D.M., Murray R., et al. Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
15. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345(13):948-955.
16. Mittan D., Shuko L., Miller E., et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87(8):3656-3661.
17. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352(2):154-164.
18. Smith M.R., Lee W.C., Brandman J., et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with non-metastatic prostate cancer. J Clin Oncol 2005, 23(31):7897-7903.
19. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294(2):238-244.
20. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341(24):1781-1788.
21. Bilezikian J.P. Osteoporosis in men. J Clin Endocrinol Metab 1999, 84(10):3431-3434.
22. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167(6):2361-2367.
23. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000, 163(1):181-186.
24. Maillefert J.F., Sibiliam J., Michel F., et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999, 161(4):1219-1222.
25. Diamond T.H., Thornley S.W., Sekel R., et al. Hip fracture in elderly men: prognostic factors and outcomes. Med J Aust 1997, 167(8):412-415.
26. Smith M.R., Boyce S.P., Moyneur E., et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006, 175(1):136-139.
27. Slemenda C.W., Longcope C., Zhou L., et al. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997, 100(7):1755-1759.
28. Khosla S., Melton L.J., Atkinson E.J., et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998, 83(7):2266-2274.
29. Greendale G.A., Edelstein S., Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997, 12(11):1833-1843.
30. Leder B.Z., Smith M.R., Fallon M.A., et al. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001, 86(2):511-516.
31. Rogers M.J., Watts D.J., Russel R.G. Overview of bisphosphonates. Cancer 1997, 80:1652-1660.
32. Lee R.J., Saylor P.J., Smith M.R. Treatment and prevention of bone complications from prostate cancer. Bone 2011, 48:88-95.
33. Berenson J.R., Lichtenstein A., Porter L., et al. The myeloma Aredia Study G. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488-493.
34. Hortobagyl G.N., Theriault R.L., Porter L., et al. The Protocol 19 Aredia Breast Cancer Study G. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996, 335:1785-1792.
35. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003, 98:1735-1744.
36. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150-3157.
37. Lee R.J., Saylor P.J., Smith M.R. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer 2010, 8(1):29-36.
38. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377(9768):813-822.
39. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354(8):821-831.
40. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43(2):222-229.
41. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
42. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26(30):4875-4882.
43. Smith M.R., Egerdie B., Hernandez Toriz N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361(8):745-755.
44. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008, 179:152-155.
45. Greenspan S.L., Nelson J.B., Trump D.L., et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. Ann Intern Med 2007, 146:416-424.
46. Diamond T.H., Winters J., Smith A., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 2001, 92:1444-1450.
47. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
48. Michaelson M.D., Kaufman D.S., Lee H., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007, 25:1038-1042.
49. Morabito N., Gaudio A., Lasco A., et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res 2004, 19:1766-1770.
50. Seeman E., Bianchi G., Khosla S., et al. Bone fragility in men-where are we?. Osteoporos Int 2006, 17(11):1577-1583.
51. Kanis J.A., Johnell O., Oden A., et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19(4):385-397.
52. Watts N.B., Lewiecki E.M., Miller P.D., et al. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom 2008, 11(4):473-477.
53. Saylor P.K., Kaufman D.S., Michaelson M.D., et al. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010, 183:2200-2205.
54. Smith M.R., Saad F., Egerdie B., et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 2009, 182(6):2670-2675.
55. Smith M.R., Fallon M.A., Lee H., et al. Raloxifene to prevent gonadotropin releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:3841-3846.
56. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
57. Small E.J., Smith M.R., Seaman J.J., et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003, 21:4277-4284.
58. Ernst D.S., Tannock I.F., Winquist E.W., et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003, 21:3335-3342.
59. Dearnaley D.P., Sydes M.R., Mason M.D., et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst 2003, 95:1300-1311.
60. Dearnaley D.P., Mason M.D., Parmar M.K., et al. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009, 10:872-876.
61. Mason M.D., Sydes M.R., Glaholm J., et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007, 99:765-776.
62. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005, 23:2918-2925.
63. Wirth M, Tammela T, DeBruyne F, et al. Effectiveness of zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients. A randomised, open label, multicenter study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). A report of the ZEUS study. 2008 Genitourinary Cancers Symposium [abstract no: 184]. Genitourinary Cancer Symposium. American Society of Clinical Oncology. San Francisco, February 14-16, 2008.
64. Smith M., Saad F., Coleman R., et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2011, 379(9810):39-46.
65. Quilty P.M., Kirk D., Bolger J.J., et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994, 31:33.
66. Porter A.T., McEwan A.J., Powe J.E., et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993, 25:805.
67. Oosterhof G.O., Roberts J.T., de Reijke T.M., et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003, 44:519.
68. Serafini A.N., Houston S.J., Resche I., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998, 16:1574.
69. Sartor O., Reid R.H., Hoskin P.J., et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004, 63:940.
70. Farhanghi M., Holmes R.A., Volkert W.A., et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992, 33:1451.
71. Kossman S.E., Weiss M.A. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer 2000, 88:620.
72. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in- class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract: 8]. Oral Abstract Session A.